Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Early humoral immune responses to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus …
(SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus …
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …
An engineered IgG–VHH bispecific antibody against SARS‐CoV‐2 and its variants
H Chi, L Wang, C Liu, X Cheng, H Zheng, L Lv… - Small …, 2022 - Wiley Online Library
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) neutralizing antibodies
are shown to be effective therapeutics for providing coronavirus disease 2019 (COVID‐19) …
are shown to be effective therapeutics for providing coronavirus disease 2019 (COVID‐19) …
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes
coronavirus disease 2019 (COVID-19), primarily infects cells at mucosal surfaces. Serum …
coronavirus disease 2019 (COVID-19), primarily infects cells at mucosal surfaces. Serum …
[PDF][PDF] Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody
Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We
identified panels of fully human monoclonal antibodies (mAbs) from eight large …
identified panels of fully human monoclonal antibodies (mAbs) from eight large …
Is SARS-CoV-2 neutralized more effectively by IgM and IgA than IgG having the same Fab region?
Y Pisil, Z Yazici, H Shida, T Miura - Pathogens, 2021 - mdpi.com
Recently, recombinant monoclonal antibodies (mAbs) of three Ig isotypes (IgG, IgA, and IgM)
sharing the same anti-spike protein Fab region were developed; we evaluated their …
sharing the same anti-spike protein Fab region were developed; we evaluated their …
[HTML][HTML] An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variants
W Zeng, X Jia, X Chi, X Zhang, E Li, Y Wu, Y Liu… - International Journal of …, 2023 - Elsevier
Abstract SARS-CoV-2, a type of respiratory virus, has exerted a great impact on global
health and economy over the past three years. Antibody-based therapy was initially …
health and economy over the past three years. Antibody-based therapy was initially …
SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses
Background Mucosal antibodies play a key role in the protection against SARS-CoV-2
infection in the upper respiratory tract, and potentially in limiting virus replication and …
infection in the upper respiratory tract, and potentially in limiting virus replication and …
Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models
Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We
identified panels of fully human monoclonal antibodies (mAbs) from eight large phage …
identified panels of fully human monoclonal antibodies (mAbs) from eight large phage …
Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
Z Ling, C Yi, X Sun, Z Yang, B Sun - Science China Life Sciences, 2023 - Springer
Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been
approved in many countries, with most being developed based on the original strain of …
approved in many countries, with most being developed based on the original strain of …